TREATMENT OF RETINAL VASCULAR DISEASE USING PROGENITOR CELLS

• US 20180015129A1
• Filed: 06/28/2017
• Published: 01/18/2018
• Est. Priority Date: 07/05/2016
• Status: Abandoned Application

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Harris, Ian R., Dejneka, Nadine
• Application Number:
  US15/636,140
• Publication Number:
  US 20180015129A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.

Claims

1. A method of inhibiting or reducing retinal neovascularization in retinopathy comprising administering a homogenous population of human umbilical cord tissue-derived cells to the eye of a subject, wherein the cell population is isolated from human umbilical cord tissue substantially free of blood, is capable of self-renewal and expansion in culture, expresses CD13, CD90 and HLA-ABC, and does not express CD31, CD34, CD45 and CD117.

2. The method of claim 1, wherein the retinopathy is diabetic retinopathy.

3. The method of claim 1, wherein the cell population further has the following characteristics:

a) potential for 40 population doublings in culture;

b) expresses CD10, CD44 and CD73; and

c) does not express CD141.

4. The method of claim 1, wherein the cell population has increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

5. The method of claim 1, wherein administration to the eye is selected from intravitreal injection or subretinal injection.

6. The method of claim 1, wherein the cell population is administered at 1,000 to 20,000 cells.

7. The method of claim 1, wherein the cell population is administered by intravitreal injection with 4,000 to 20,000 cells.

8. The method of claim 1, wherein the cell population is administered by subretinal injection at 1,000 to 4,000 cells.

15. The method of claim 1, wherein the cell population is administered by subretinal injection at 3×

10⁷ cells.

9. A method of inhibiting or reducing vascular leakage in retinopathy comprising administering a homogenous population of human umbilical cord tissue-derived cells to the eye of a subject, wherein the cell population is isolated from human umbilical cord tissue substantially free of blood, is capable of self-renewal and expansion in culture, expresses CD13, CD90 and HLA-ABC, and does not express CD31, CD34, CD45 and CD117.

10. The method of claim 9, wherein the retinopathy is diabetic retinopathy.

11. The method of claim 9, wherein the cell population further has the following characteristics:

a) potential for 40 population doublings in culture;

b) expresses CD10, CD44 and CD73; and

c) does not express CD141.

12. The method of claim 9, wherein the cell population has increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

13. The method of claim 9, wherein administration to the eye is selected from intravitreal injection or subretinal injection.

14. The method of claim 9, wherein the cell population is administered at 1,000,000 to 30,000,000 cells.